论文部分内容阅读
目的：探讨新辅助化疗对直肠癌患者的临床疗效。方法选取2011年1月~2013年6月我院收治的直肠癌患者96例，随机分为观察组和对照组各48例，对照组实施直肠癌根治术，观察组在实施直肠癌根治术前进行新辅助化疗，比较两组临床疗效。结果观察组经术前新辅助化疗后，多数患者肿瘤体积变小(33例，占68.8%)；观察组经术前新辅助放化疗后，肿瘤分期为Ⅰ期、Ⅱ期的患者明显增多，肿瘤分期为Ⅲ期、Ⅳ期的患者明显减少，差异有统计学意义(<0.05)；分别对两组患者进行随访，观察组患者术后1年、术后2年存活率均明显高于对照组患者，差异显著有统计学意义(<0.05)。结论对直肠癌患者进行新辅助化疗疗效显著，值得在临床推广。“,”Objective To evaluate the clinical efficacy of neoadjuvant chemotherapy in patients with colorectal cancer.Methods 96 patients with colorectal cancer in January 2011~2013 in June in our hospital,were randomly divided into observation group and control group,48 cases in the control group to implement colorectal cancer resection,observation group in the implementation of colorectal cancer resection before neoadjuvant chemotherapy, comparative clinical efficacy.Results The study group before and after neoadjuvant chemotherapy after surgery,most patients with smaller tumor volume (33 cases,68.8%);after the observation group after neoadjuvant chemotherapy,tumor stageⅠstage, IIstage patients increased significantly,tumor stageⅢ,Ⅳstage patients was significantly reduced,the difference was statistically significant ( <0.05);two groups of patients were followed up,patients in the observation group 1 year after 2-year survival rate was significantly higher patients in the control group,significant difference was statistically significant( <0.05).Conclusion Patients with colorectal cancer to neoadjuvant chemotherapy significantly worthy of promotion.